Blogs

Pfizer will present more than 50 abstracts, involving more than 15 clinical-stage assets across solid and hematologic tumors and 12 moA, at the ASCO in Chicago from June 2-6, 2017. New data will be featured in 9 oral presentations from company-sponsored clinical trials, including a late-breaker on the investigational compound dacomitinib in locally advanced or metastatic NSCLC with EGFR-activating mutation, which will be featured in the official ASCO press program. Other abstracts provide insights into

Janssen will present new data for both approved and investigational oncology compounds at ASCO 2017 Annual Meeting. 19 company-sponsored abstracts have been accepted for presentation, including for abiraterone acetate, daratumumab and ibrutinib. Most notably, Phase 3 pivotal trial results for abiraterone acetate will be featured in the ASCO Press Briefing on Saturday, June 3rd, which have also been selected for inclusion in the Plenary Session on Sunday, June 4th.  

Celgene will demonstrate its broad range of Oncology Clinical Development Program evaluating its investigational pipeline & marketed products at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US, 2-6 June 2017. Presentations will include multiple solid tumor and blood cancers while highlighting the value of innovative research. In multiple myeloma, abstracts will continue to support the role of Celgene’s IMiD® therapies as the foundation of multiple myeloma research, including in the

The remote patient management or tele-healthcare as a concept is only starting to take off in Oncology. The readouts, though limited by their small sample size, have shown positive impact of technology on care providers, patient outcomes and the overall cost burden. Normally, larger studies would be needed to validate these observations. It is unclear if such large scale publicly funded studies will be undertaken. It is more likely that market competition will drive individual

Bristol-Myers Squibb Research Showcases Expansive Oncology Clinical Development Program and Commitment to Exploring Novel Combinations at ASCO 2017 More than 80 presentations (including16 oral presentations and 7 poster discussions), highlighting data from Company-sponsored studies, collaborations and IS research spanning 20 types of cancer, with focus on research of precision therapies aimed at improving standards of care. The presentations represent the breadth of the Company’s Oncology research portfolio, including monotherapy and combination studies of Opdivo and

AstraZeneca (AZ), along with its global biologics research and development arm, MedImmune, will demonstrate how it is rapidly delivering on the Company’s science-led strategy for transformational cancer medicine development at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US, 2-6 June 2017. With three new oncology medicines addressing the unmet needs of patients with ovarian, lung, and bladder cancers approved in under three years, AZ is now halfway to delivering on